Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: Results of the GEPARDUO trial

Annals of Surgical Oncology

Volumn 13, Issue 11, 2006, Pages 1434-1442

  Loibl, Sibylle ^a,b   Von Minckwitz, Gunter ^a,b   Raab, Günther ^c,k   Blohmer, Jens Uwe ^d   Costa, Serban Dan ^e   Gerber, Bernd ^f   Eidtmann, Holger ^g   Petrich, Simone ^a   Hilfrich, Jörn ^h   Jackisch, Christian ⁱ   Bois, Andreas Du ^j   Kaufmann, Manfred ^a  

^a GOETHE UNIVERSITY   (Germany)

^b GERMAN BREAST GROUP   (Germany)

^c Orthopädische Praxis München   (Germany)

^d MARTIN LUTHER KRANKENHAUS   (Germany)

^e OTTO VON GUERICKE UNIVERSITY   (Germany)

^f KLINIKUM NÜRNBERG   (Germany)

^g UNIVERSITY OF KIEL   (Germany)

^h Henriettenstiftung   (Germany)

ⁱ Klinikum Offenbach   (Germany)

^j DR HORST SCHMIDT KLINIKEN   (Germany)

^k Abteilung für Orthopädie und Endoprothetik   (Germany)

more..

Author keywords

Breast cancer; Breast conservation; Neoadjuvant therapy; Re excision; Surgery

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASTECTOMY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REOPERATION; SURGICAL TECHNIQUE; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; MASTECTOMY; MIDDLE AGED; NEOADJUVANT THERAPY; PROSPECTIVE STUDIES; TAXOIDS;

EID: 33750969693     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-006-9011-2     Document Type: Article

References (41)

1. Kaufmann M, Hortobagyi GN, Goldhirsch A. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 2006; 24:1940-9.
2. Hortobagyi GN, Singletary E, Strom EA. (2000) Treatment of locally advanced and inflammatory breast cancer. In: Harris J, ed. Diseases of the Breast 2nd ed. Lippincott Williams & Wilkins, Philadelphia, pp 645-60.
3. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16:2483-93.
4. van der Hage JA, van de Velde CJ, Julien JP, et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001; 19:4224-37.
5. Scholl SM, Fourquet A, Asselain B, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial - S6. Eur J Cancer 1994; 30A:645-52.
6. Broet P, Scholl SM, De la Rochefordiere A, et al. Short and long term effects on survival in breast cancer patients treated by primary chemotherapy: an updated analysis of a randomised trial. Breast Cancer Res Treat 1999; 58:151-6.
7. Scholl SM, Pierga J, Asselain B, et al. Breast tumor response to primary chemotherapy predicts local and distant control as well as survival. Eur J Cancer 1995; 31:1969-75.
8. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17:460-9.
9. Chollet P, Amat S, Cure H, et al. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer 2002; 86:1041-106.
10. Thomas E, Holmes FA, Smith TL, et al. The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial. J Clin Oncol 2004; 22:2294-302.
11. Bonnadonna G, Veronesi U, Brambilla C, et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 1990; 82:1539-45.
12. Makris A, Powles TJ, Ashley SE, et al. A reduction of requirements for mastectomy in a randomised trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 1998; 9:1179-84.
13. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997; 15:2483-93.
14. Shen J, Valero V, Buchholz TA, et al. Effective local control and long-term survival in patients with T4 locally advanced breast cancer treated with breast conservation therapy. Ann Surg Oncol 2004; 11:854-60.
15. Kaufmann M, von Minckwitz G, Smith R, et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 2003; 21:2600-8.
16. Mauri D, Pavlidis N, Ioannidis JPA. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a metaanalysis. J Natl Cancer Inst 2005; 97:188-94.
17. Chen AM, Meric-Bernstam F, Hunt KK, et al. Breast conservation after neoadjuvant chemotherapy. Cancer 2005; 103:689-95.
18. Sadetzki S, Oberman B, Zipple D, et al. Breast conservation after neoadjuvant chemotherapy. Ann Surg Oncol 2005; 12:1-8.
19. von Minckwitz G, Raab G, Caputo A, et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 2005; 23:2676-85.
20. Papa M, Zippel D, Koller M, et al. Positive margins of breast biopsy: is reexcision always necessary?. Surg Oncol 1999; 70:167-71.
21. Cellini C, Hollenbeck ST, Christis P, et al. Factors associated with residual breast cancer after re-excision for close or positive margins. Ann Surg Oncol 2004; 11:915-20.
22. Fisher B, Brown E, Mamounas E, et al. The effect of preoperative chemotherapy on loco-regional disease in women with operable breast cancer: findings from NSABP B-18. J Clin Oncol 1997; 15:2483-93.
23. Dieras V, Fumoleau P, Romieu G, et al. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol 2004; 22:4958-65.
24. Untch M, Konency G, Ditsch N, et al. Dose-dense sequential epirubicin-paclitaxel as preoperative treatment of breast cancer: results of a randomised AGO study (abstract 133). Proc Am Soc Clin Oncol 2002; 21:34a.
25. Noh WC, Paik NS, Kim MS. Ipsilateral breast tumor recurrence after breast-conserving therapy: a comparison of quadrantectomy versus lumpectomy at a single institution. World J Surg 2005; 29:1001-6.
26. Veronesi U, Volterrani F, Luini A, et al. Quadrantectomy versus lumpectomy for small size breast cancer. Eur J Cancer 1990; 26:671-3.
27. Fleming FJ, Hill AD, McDermott EW, O'Doherty A, O'Higgins NJ, Quinn CM. Intraoperative margin assessment and re-excision rate in breast conserving surgery. Eur J Surg Oncol 2004; 30:233-7.
28. Weber S, Storm FK, Stitt J, Mahvi DM. The role of frozen section analysis of margins during breast conservation surgery. Cancer J Sci Am 1997; 3:273-7.
29. von Minckwitz G, Blohmer JU, Raab G, et al. In vivo chemosensitivity- adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol 2005; 16:56-63.
30. Cocquyt VF, Blondeel PN, Depypere HT, et al. Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma. Eur J Surg Oncol 2003; 29:361-7.
31. Mathieu MC, Rouzier R, Llombart-Cussac A, et al. The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer 2004; 40:342-51.
32. Newman LA, Buzdar AU, Singletary SE, et al. A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility. Ann Surg Oncol 2002; 9:228-34.
33. du Bois A, Misselwitz B, Wagner U, et al. Disease Management Programm (DMP) Brustkrebs und Versorgungsstruktur bei der operativen Therapie des Mammakarzinoms in Hessen 2002. Geburtshilfe Frauenheilkd 2004; 64:261-70.
34. Hiotis K, Ye W, Sposto R, Skinner KA. Predictors of breast conservation therapy. Size is not all that matters. Cancer 2005; 103:892-9.
35. Morrow M, Bucci C, Rademaker A. Medical contraindications are not a major factor in the underutilization of breast conserving therapy. J Am Coll Surg 1998; 186:269-74.
36. Kuerer HM, Singletary SE, Buzdar AU, et al. Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma. Am J Surg 2001; 182:601-8.
37. Yeh E, Slanetz P, Kopans DB, et al. Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. AJR Am J Roentgenol 2005; 184:868-77.
38. Rosen EL, Blackwell KL, Baker JA, et al. Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. AJR Am J Roentgenol 2003; 181:1275-82.
39. Veronesi U, Bonnadonna G, Zurrida S, et al. Conservation surgery after primary chemotherapy in large carcinomas of the breast. Ann Surg 1995; 222:612-8.
40. Margolese RG. Surgical considerations in preoperative chemotherapy of breast cancer. Recent Results Cancer Res 1998; 152:193-201.
41. Chen AM, Meric-Bernstam F, Hunt KK, et al. Breast conservation after neoadjuvant chemotherapy. A prognostic index for clinical decision-making. Cancer 2005; 103:689-95.